What moves our stock price? Evidence that LymPro i
Post# of 30029
Posted On: 09/07/2014 10:44:31 AM
What moves our stock price? Evidence that LymPro is the real deal and will bring in handsome revenue soon!! That's it. Everything else is simply a mood enhancer. Phenoguard potential developments are nice, Eltoprazine future potential is intriguing, and MANF's endless potential could fill an afternoon to discuss.
But the only thing Wall Street cares about is MONEY! They want stocks to SHOW THEM THE MONEY!! Science is nice, and Chinese eat rice, but Money making ability is the meat and potatoes the Market cares about.
MANF data is nice.
MANF orphan designation is nicer.
MANF orphan, fast track, break through designation is even nicer still.
But a MANF Partnership on Retinitis or Wolframs/Diabetes is the only thing that will really move our stock upwards. I don't know if Gerald will secure one of these any easier than he has secured a JV partner for LymPro. I think he might get orphan status for a couple indications but I'm not sure he will secure a partner until after we have completed a phase 1/2 trial first.
In the mean time, our stock may remain lower than we'd hoped for. Maybe we up list in the .20 to .30 cent range. But LymPro revenue will be on it's way and will get us through 2015 & 2016 fairly nicely until MANF has graduated from High School and the NBA can start considering it more seriously. MANF is a sophomore in H.S. right now. It is playing on the Varsity and will probably make All League, if not All State this year. But the NBA doesn't draft kids until they graduate from H.S, not even Lebron!
Gerald knows this. He should probably align his comments to our more moderate progress for the next 18 months. If we up list at .25 cents in November, that is darn good! If we get to .50 cents by the summer of 2015 (Pre-RS numbers) that is also darn good.If we get to $1.00 by early 2016 when MANF starts human clinical trials and LymPro revenue is paying for it, that is also darn good!!
Getting up to $3 to $5 dollars is going to require more than 12 to 18 months IMHO. I could be wrong, I frequently am. But I'm just trying to be realistic and count my blessings for what AMBS is achieving. We are trading at .106 cents because that is the value the market places on what we've achieved. But getting LymPro producing revenue will boost us to a much higher level: 25 to .50 cents. It will grow from there. But let's not get all dejected because we won't trade above $1.00 this year, pre-RS.
MANF data is a mood enhancer. A MANF Partnership is a brain transplant, an Albert Einstein brain!! Let's not get our hopes up that MANF data will pop us up much.
Hopefully this new PR Firm we've hired will align our PRs with reality in such a way that shareholder expectations will not get out of whack so easily.
We're going to get rich, but not over night.
But the only thing Wall Street cares about is MONEY! They want stocks to SHOW THEM THE MONEY!! Science is nice, and Chinese eat rice, but Money making ability is the meat and potatoes the Market cares about.
MANF data is nice.
MANF orphan designation is nicer.
MANF orphan, fast track, break through designation is even nicer still.
But a MANF Partnership on Retinitis or Wolframs/Diabetes is the only thing that will really move our stock upwards. I don't know if Gerald will secure one of these any easier than he has secured a JV partner for LymPro. I think he might get orphan status for a couple indications but I'm not sure he will secure a partner until after we have completed a phase 1/2 trial first.
In the mean time, our stock may remain lower than we'd hoped for. Maybe we up list in the .20 to .30 cent range. But LymPro revenue will be on it's way and will get us through 2015 & 2016 fairly nicely until MANF has graduated from High School and the NBA can start considering it more seriously. MANF is a sophomore in H.S. right now. It is playing on the Varsity and will probably make All League, if not All State this year. But the NBA doesn't draft kids until they graduate from H.S, not even Lebron!
Gerald knows this. He should probably align his comments to our more moderate progress for the next 18 months. If we up list at .25 cents in November, that is darn good! If we get to .50 cents by the summer of 2015 (Pre-RS numbers) that is also darn good.If we get to $1.00 by early 2016 when MANF starts human clinical trials and LymPro revenue is paying for it, that is also darn good!!
Getting up to $3 to $5 dollars is going to require more than 12 to 18 months IMHO. I could be wrong, I frequently am. But I'm just trying to be realistic and count my blessings for what AMBS is achieving. We are trading at .106 cents because that is the value the market places on what we've achieved. But getting LymPro producing revenue will boost us to a much higher level: 25 to .50 cents. It will grow from there. But let's not get all dejected because we won't trade above $1.00 this year, pre-RS.
MANF data is a mood enhancer. A MANF Partnership is a brain transplant, an Albert Einstein brain!! Let's not get our hopes up that MANF data will pop us up much.
Hopefully this new PR Firm we've hired will align our PRs with reality in such a way that shareholder expectations will not get out of whack so easily.
We're going to get rich, but not over night.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼